SpineGuard Announces Its Full-Year 2023 Financial Results and Its First Quarter 2024 Sales

Regulatory News:

SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its DSG (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, announced today its full-year 2023 financial results, for the financial year ending December 31, 2023, as approved by the Board of Directors on April 17, 2024, and its first quarter 2024 sales.

Q1 2024 revenue

€ thousands – IFRS (unaudited)	2024	2023	Variance
First Quarter	1,351	1,271	+6.3%

2023 Financial Results

€ thousands – IFRS audited	2023	2022
Revenue	4,313	5,600
Gross Margin	3,379	4,715
Gross margin (% of revenue)	78.3 %	84.2 %
Sales, distribution & marketing	4,065	3,700
Administrative costs	1,800	1,640
Research & Development	1,434	901
Operating profit / (loss)	-3,919	-1,526
Non-recurring operating costs	-57	-135
Financial Result	-225	-427
Income Tax	18	-305
Net profit / (loss)	-4,183	-2,393
EBITDA	-3,544